Comparison of Epidemiological, Clinical, and Biological Features of Invasive Aspergillosis in Neutropenic and Nonneutropenic Patients: A 6‐Year Survey

Cornillet, A.; Camus, Christophe; Nimubona, Stanislas; Gandemer, Virginie; Tattevin, Pierre; Belleguic, Chantal; Chevrier, S.; Meunier, Catherine; Le-Bert, Carolina; Aupée, Martine; Caulet‐Maugendre, Sylvie; Faucheux, Monique; Lelong, Bernard; Leray, Emmanuelle; Guiguen, Claude; Gangneux, Jean‐Pierre

doi:10.1086/505870

Cited by 301 publications

(235 citation statements)

References 33 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…Aspergillus fumigatus and Pseudomonas aeruginosa in these patients [38][39][40]. As PTX3 is known to be involved in clearance of apoptotic cells, a reduction of the level of this molecule could lead to accumulation of apoptotic cells in COPD [41,42], which is a possible risk factor for an autoimmune component in COPD pathogenesis.…”

Section: Discussionmentioning

confidence: 98%

COPD is associated with reduced pulmonary interstitial expression of pentraxin-3

Pottelberge

Bracke²,

Pauwels³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

Pentraxin (PTX)3 is involved in antimicrobial defence, apoptotic cell clearance and extracellular matrix stability. As these processes are altered in chronic obstructive pulmonary disease (COPD), we aimed to investigate PTX3 expression in patients with this disease.PTX3 expression was quantified by immunohistochemical staining of lung tissue from neversmokers, smokers without COPD, and in patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I, II and III-IV. mRNA expression was examined in total lung tissue by quantitative RT-PCR. PTX3 concentration was measured in induced sputum and plasma by ELISA.PTX3 is mainly localised in the interstitium of the small airways and alveolar walls. There were no significant differences in pulmonary, sputum and plasma PTX3 expression between study groups. However, PTX3 expression in small airways correlated significantly with forced expiratory volume in 1 s (r50.35, p50.004). In the alveolar walls, PTX3 expression correlated significantly with carbon monoxide transfer coefficient (r50.28, p50.04). In sputum, PTX3 levels were highly correlated with the number of neutrophils. Finally, systemic levels of PTX3 tended to be lower in severe COPD compared with mild COPD.In COPD, airflow limitation and reduced transfer coefficient for carbon monoxide are associated with lower pulmonary interstitial expression of PTX3.

show abstract

Section: Discussionmentioning

confidence: 98%

COPD is associated with reduced pulmonary interstitial expression of pentraxin-3

Pottelberge

Bracke²,

Pauwels³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…attack rate) has been reported extensively in patients with various hematologic diseases. 3,4,7,14,[25][26][27] While IA increased in the 1980s-1990s in the general population, 2 no reduction in IA incidence has been observed in hematology patients. 3,28 In our study, the decrease in IA incidence could be explained by medical prophylaxis with posaconazole which has been used systematically in all patients with AML in induction chemotherapy since 2007 in our setting.…”

Section: Discussionmentioning

confidence: 99%

“…Recently-observed improvement in survival 9 has been related to changes in clinical practices, and despite greater risk of aplasia, the prognosis of hematologic diseases has improved in recent years with more efficient chemotherapies. 10 IA incidence varies according to underlying hematologic disease and studies reported, being between 5% and 24% in acute leukemia patients [11][12][13][14] and between 3% and 11% in allogeneic stem cell transplantation. [15][16][17] Medical prophylaxis with posaconazole [18][19] and/or prevention strategies taking environmental factors into account [20][21] could have contributed to a decrease in IA incidence.…”

Section: Introductionmentioning

confidence: 99%

Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

Nicolle¹,

Bénet²,

Thiébaut³

et al. 2011

Haematologica

View full text Add to dashboard Cite

BackgroundThe study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis. Design and MethodsA prospective survey of invasive aspergillosis cases was undertaken between January 2004 and December 2009 in the hematology department of a university hospital. Meetings with clinicians, mycologists and infection control practitioners were organized monthly to confirm suspected aspergillosis cases. Demographic characteristics, clinical and complementary examination results were recorded prospectively. Information on hospitalization was extracted from administrative databases. Invasive aspergillosis diagnosis followed the European Organization for Research and Treatment of Cancer criteria, and proven and probable IA cases were retained. A descriptive analysis was conducted with temporal trends of invasive aspergillosis incidence assessed by adjusted Poisson regression. ResultsOverall, 4,073 hospitalized patients (78,360 patient-days) were included in the study. In total, 127 (3.1%) patients presented invasive aspergillosis. The overall incidence was 1.6 per 1,000 patient-days (95% confidence interval: 1.4, 1.9) with a decrease of 16% per year (-1%, -28%). The incidence was 1.9 per 1,000 patient-days (1.5, 2.3) in acute myeloid leukemia patients with a decrease of 20% per year (-6%, -36%). Serum Aspergillus antigen was detected in 89 (71%) patients; 29 (23%) had positive cultures, and 118 (93%), abnormal lung CT scans. One-month mortality was 13%; 3-month mortality was 42%. Mortality tended to decrease between 2004 and 2009. ConclusionsInvasive aspergillosis incidence and mortality declined between 2004 and 2009. Knowledge of invasive aspergillosis characteristics and its clinical course should help to improve the management of these patients with severe disease.Key words: invasive aspergillosis, surveillance, hematologic disease, incidence, hospital. 2004 . Haematologica 2011 96(11):1685-1691. doi:10.3324/haematol.2011 Citation: Nicolle M-C, Bénet T, Thiebaut A, Bienvenu A-L, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X, Nicolini F-E, De Monbrison F, Piens M-A, Picot S, Michallet M, and Vanhems P. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from

show abstract

“…Invasive aspergillosis (IA) is the most frequently occurring invasive fungal infection in immunocompromised patients (Kontoyiannis et al, 2010;Neofytos et al, 2009), with a high mortality rate ranging from 27 to 89% (Cornillet et al, 2006;Pagano et al, 2010). Early and accurate diagnosis followed by appropriate antifungal therapy is vital for a favourable outcome .…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis

Pan

Zhang

et al. 2015

Journal of Medical Microbiology

View full text Add to dashboard Cite

A novel lateral-flow device (LFD) has been invented for use as a diagnostic tool for invasive aspergillosis (IA). We conducted a meta-analysis to assess the diagnostic accuracy of the device. Published studies that used the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria and provided sufficient data were included. Two reviewers independently collected the data from each study and assessed the risk bias using the Quality Assessment of Diagnostic Accuracy Studies-2. The pooled sensitivity, specificity and diagnostic odds ratio (DOR) were computed and reported with a 95 % confidence interval 90 (95 % CI,) in the LFD test using serum. We concluded that the Aspergillus LFD had a good diagnostic value in immunocompromised patients at risk of IA. The BAL LFD might have a better performance than the serum LFD test.

show abstract

Comparison of Epidemiological, Clinical, and Biological Features of Invasive Aspergillosis in Neutropenic and Nonneutropenic Patients: A 6‐Year Survey

Abstract: This survey at a whole institution underlines the high number of cases of invasive aspergillosis among nonneutropenic patients, with an overall mortality rate that was significantly higher than that for neutropenic patients.

Cited by 301 publications

References 33 publications

COPD is associated with reduced pulmonary interstitial expression of pentraxin-3

COPD is associated with reduced pulmonary interstitial expression of pentraxin-3

Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis

Contact Info

Product

Resources

About